VAXCYTE INC's ticker is PCVX and the CUSIP is 92243G108. A total of 75 filers reported holding VAXCYTE INC in Q2 2021. The put-call ratio across all filers is - and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $20,189,661 | +5.9% | 396,031 | +3.8% | 0.00% | 0.0% |
| Q2 2023 | $19,059,902 | +68.9% | 381,656 | +26.8% | 0.00% | +100.0% |
| Q1 2023 | $11,283,204 | -23.5% | 301,046 | -2.1% | 0.00% | -33.3% |
| Q4 2022 | $14,751,721 | +242.3% | 307,648 | +71.3% | 0.00% | +200.0% |
| Q3 2022 | $4,310,000 | +26.9% | 179,570 | +15.1% | 0.00% | 0.0% |
| Q2 2022 | $3,396,000 | -7.7% | 156,077 | +2.4% | 0.00% | 0.0% |
| Q1 2022 | $3,680,000 | +6.3% | 152,364 | +4.7% | 0.00% | 0.0% |
| Q4 2021 | $3,461,000 | -0.8% | 145,473 | +5.7% | 0.00% | 0.0% |
| Q3 2021 | $3,490,000 | +30.8% | 137,598 | +16.1% | 0.00% | 0.0% |
| Q2 2021 | $2,668,000 | +59.2% | 118,506 | +39.7% | 0.00% | – |
| Q1 2021 | $1,676,000 | -4.3% | 84,837 | +28.7% | 0.00% | – |
| Q4 2020 | $1,752,000 | -33.1% | 65,940 | +24.4% | 0.00% | -100.0% |
| Q3 2020 | $2,618,000 | – | 53,015 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Medicxi Ventures Management (Jersey) Ltd | 1,049,893 | $53,523,545 | 17.09% |
| Pivotal bioVenture Partners Investment Advisor LLC | 793,036 | $40,429,128 | 16.12% |
| Kynam Capital Management, LP | 1,302,407 | $66,396,709 | 10.86% |
| RA Capital Management | 7,891,254 | $402,296,129 | 7.92% |
| COMMODORE CAPITAL LP | 1,100,000 | $56,078,000 | 6.56% |
| GREAT POINT PARTNERS LLC | 531,211 | $27,081,137 | 4.93% |
| ACUTA CAPITAL PARTNERS, LLC | 121,022 | $6,169,702 | 4.14% |
| Frazier Life Sciences Management, L.P. | 1,164,405 | $59,361,367 | 3.94% |
| Novo Holdings A/S | 845,000 | $43,078,100 | 3.18% |
| BRAIDWELL LP | 1,619,553 | $82,564,812 | 2.61% |